Compare McCormick & Company, Incorporated (MKC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Sana Biotechnology Inc — how do they compare? McCormick & Company, Incorporated trades at $53.03 (market cap $14.22B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: McCormick & Company, Incorporated is far larger — about 12.6× Sana Biotechnology Inc's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MKC | SANA | |
|---|---|---|
Market Cap | $14.22B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $72.26 | $5.92 |
52-Week Low | $45.60 | $2.68 |
Enterprise Value | $18.82B | $1.05B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick (MKC) trades at $52.93, down 0.38% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion merger with Unilever's food business, expected to complete in 2027, driving positive analyst sentiment and a consensus price target of $59.67.
The outlook for MKC is positive, supported by margin expansion, strategic acquisitions, and the potential upside from the Unilever deal. Key risks include integration challenges from the merger, soft consumer volumes, and competitive pressures. With a 4% dividend yield and 35% upside to some price targets, the stock presents a compelling opportunity for long-term investors despite near-term volatility.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
